Is AMGN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

6,091 people get AMGN articles and Market Currents by email alert.

Get email alerts on AMGN »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Will Generic Competitors Of Enbrel Affect Amgen's Stock Price?
Bio Vantage • Fri, Jun 14 • 2 Comments
Amgen Is A Value And Dividend Growth Story
Abba's Aces • Thu, Jun 13
Amgen Inc. Is A Buy For Short Term Investors
Investment Analytics • Thu, Jun 6 • 1 Comment
Generic Threats To Amgen's Biologics
Emerging Equities • Thu, Jun 6
Amgen: Financial Analysis And Valuation
Shankar N • Fri, May 24
Here's Why Amgen Shares Are Worth $117 To $126 Today
Stephen Barnes • Sat, May 18 • 12 Comments
EPO Pills: A Challenge For Amgen And Johnson & Johnson
Peter Geschek • Thu, May 2
Whisper Number Impact: Earnings Preview For Amgen
WhisperNumber • Tue, Apr 23
Amgen: Long-Term Buy After A Pull Back
Efsinvestment • Sun, Apr 7 • 7 Comments
Our Model Suggests An Intrinsic Value Of $117 For Amgen
Bio Vantage • Wed, Apr 3 • 5 Comments
Four Factors Driving Amgen's Stock Price To $102
Bio Vantage • Mon, Apr 1 • 4 Comments
Amgen's And Vical's Melanoma Trials: Questions
Theodore Cohen • Wed, Mar 27 • 46 Comments
Recent Melanoma Trial Data Has Biotech Stocks Moving
The Swiss Trader • Wed, Mar 27 • 2 Comments
Amgen's Master Plan To Generate Biosimilar Blockbusters
Peter Geschek • Fri, Mar 15 • 2 Comments
Amgen And The Biosimilar Threat: Lessons From Affymax
PropThink • Fri, Mar 8 • 3 Comments
Amgen Benefits From Affymax Recall
Peter Geschek • Tue, Mar 5 • 3 Comments
Why Amgen Still Has Valuation Upside Remaining
Valuentum • Fri, Feb 15
Amgen: A Long-Term Growth Story
Biomed Group • Mon, Feb 11 • 5 Comments
Is Amgen Running Out Of Steam In 2013?
StockRiters • Tue, Jan 22
Amgen Q4 Earnings Preview: A Banner 2013 For The King Of Biotech
PropThink • Mon, Jan 14

Amgen: Equity Report And Stock Valuation
Bio Vantage • Mon, Dec 3, 2012 • 2 Comments

Today's Market: Biotech And Cable M&A The Big Stories
Matthew Smith • Mon, Jun 17
Taking Care Of Yourself And Your Property Through These Stocks
Abba's Aces • Sun, Jun 16 • 2 Comments
The Biggest Companies That Don't Pay Dividends - But May Be About To
StreetAuthority • Fri, Jun 14
Why The Amgen And Cytokinetics Agreement Is Good News
Prohost Biotech • Thu, Jun 13 • 4 Comments
Cytokinetics Receives A Vote Of Confidence From Amgen
Smith On Stocks • Thu, Jun 13 • 20 Comments
Warning: This Might Be The Most Overvalued Sector In The Market
StreetAuthority • Wed, Jun 12 • 1 Comment
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, Jun 12 • 78 Comments
4 Oversold Stocks For Patient Investors
Brian Gilmartin • Tue, Jun 11 • 8 Comments
Old-School Pharma/Biotech Dividend Paying Comparison
Abba's Aces • Thu, Jun 6
Cramer's Lightning Round - Higher Rates Are Good For First Interstate (6/5/13)
SA Editor Miriam Metzinger • Thu, Jun 6 • 1 Comment
Rexahn's Oncology Platform Led By Its Akt-1 Inhibitor Challenges Big Pharma With Ground-Breaking Cancer Therapy
Sharon di Stefano • Wed, Jun 5 • 11 Comments
Celgene Stock Still Has Plenty Of Room To Grow Due To A Strong Product Line
A John Hodge • Tue, Jun 4 • 1 Comment
Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
PropThink • Tue, Jun 4
Johnson & Johnson - Avoid This Safety Stock
The Ethical Investor • Sun, Jun 2 • 31 Comments
Keryx: Attractive In Front Of Catalyst-Rich Second Half
PropThink • Thu, May 30 • 2 Comments
Affymax Is Still Alive
EXPstocktrader • Tue, May 28 • 48 Comments
Investing In Cancer Research Is Worth The Risk: Echo He
Life Sciences Report • Fri, May 24
1 Biotech, 1 Financial And 1 Consumer Goods Company With Recent Intensive Insider Selling
Markus Aarnio • Wed, May 22 • 3 Comments
AbbVie Reaches New Highs Thanks To Humira
Efsinvestment • Wed, May 22 • 7 Comments
China Biotech In Review: SciClone Pharma In-Licenses China Rights To Heart Failure Drug
ChinaBio Today • Sun, May 19

Amgen's Management Presents at 2013 Goldman Sachs Healthcare Conference (Transcript)
Tue, Jun 11
Amgen's Management Presents at 2013 Deutsche Bank dbAccess Health Care Conference (Transcript)
Thu, May 30
Amgen, Inc. Management Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Amgen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 23 • 3 Comments
Amgen's Management Presents at Cowen and Company 33rd Annual Health Care Conference (Transcript)
Wed, Mar 6
Amgen's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Jan 23
Amgen Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 23, 2012
Amgen Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Jul 26, 2012
Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, Apr 24, 2012
Amgen's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thu, Jan 26, 2012
Amgen Management Present at The 30th Annual JPMorgan Chase Healthcare Conference (Transcript)
Mon, Jan 9, 2012
Amgen's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Mon, Oct 24, 2011
Amgen's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
Amgen's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Wed, Apr 20, 2011
Amgen's CEO Discusses Q4 2010 Results - Earnings Call Transcript
Tue, Jan 25, 2011
Amgen Management Discusses Q3 2010 Results - Earnings Call Transcript
Tue, Oct 26, 2010
Amgen Q2 2010 Earnings Call Transcript
Fri, Jul 30, 2010
Amgen Inc. Q1 2010 Earnings Call Transcript
Thu, Apr 22, 2010
Amgen, Inc. Q4 2009 Earnings Call Transcript
Mon, Jan 25, 2010
Amgen, Inc. Q3 2009 Earnings Call Transcript
Wed, Oct 21, 2009

FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone

PR Newswire (Thu, 3:11PM)
Jonathan Burton's Life Savings: Income hunters: Bank on this dividend stock play

at MarketWatch.com (Thu, 6:15AM)
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer

PR Newswire (Wed, 9:00AM)
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting

PR Newswire (Wed, 8:35AM)
Amgen To Present At The Goldman Sachs 34th Annual Global Healthcare Conference

PR Newswire (Jun 6, 2013)
Lightning Round: Amgen, Ford & More

at CNBC.com (Jun 5, 2013)
Bristol and Merck Shares Surge on Cancer Drug News

at CNBC.com (Jun 3, 2013)
Early Movers: MRK, GSK, AAPL, MSFT, BMY & More

at CNBC.com (Jun 3, 2013)
Jeff Reeves's Strength in Numbers: 3 ways to play the biotech boom

at MarketWatch.com (Jun 3, 2013)
Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma

PR Newswire (Jun 1, 2013)
Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting

PR Newswire (May 29, 2013)
Early Movers: WMT, SFD, KORS, AAPL & More

at CNBC.com (May 29, 2013)
Amgen And Astellas Announce Japan Alliance

PR Newswire (May 29, 2013)
Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference

PR Newswire (May 23, 2013)
Amgen Announces Voting Results of Annual Meeting of Stockholders

PR Newswire (May 22, 2013)
Lightning Round: CarMax, Asbury Automotive & More

at CNBC.com (May 20, 2013)
Amgen To Present At The UBS Global Life Sciences Conference

PR Newswire (May 16, 2013)
New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

PR Newswire (May 15, 2013)
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

PR Newswire (May 15, 2013)
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China

PR Newswire (May 9, 2013)

AMGN vs. ETF Alternatives

Company Description

Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) is the world’s largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 18, 7:12 PM Amgen (AMGN) ups its stake in Cytokinetics (CYTK) to 11,909,406 shares from 3,484,806 shares reported on March 21. The increase now puts AMGN's holding at 7.58% of CYTK's outstanding float. CYTK +7.4% AH. Comment! [Healthcare, On the Move]
Tuesday, June 18, 9:29 AM Cytokinetics' (CYTK) results from a Phase II trial of its of omecamtiv mecarbil treatment for heart failure have been accepted for presentation at a "Hot Line Late Breaking Trials Session" at the European Society of Cardiology Congress 2013, which is taking place from Aug. 31 until Sep. 4. Cytokinetics' hasn't revealed any results but shares are up 14.4%. Those of partner Amgen (AMGN) are a mere +0.7%. In other news, Cytokinetics is set to join the Russell Global Index on June 28. Comment! [Healthcare, On the Move]
Monday, June 17, 9:39 AM As expected, shares of Amgen (AMGN +1.3%) pop in early trading after a positive feature in Barron's over the weekend. Comment! [Healthcare, On the Move]
Saturday, June 15, 4:00 PM Amgen (AMGN) might be set for a "Barron's bump" come Monday after Reshma Kapadia says the shares may see a 20% upside just from "staying the course." Cited in the piece are CEO Robert Bradway's commitment to buybacks and dividends, cost cuts, a promising pipeline, and the shares' "sharp discount" to other large-cap biotechs. Comment! [Healthcare]
Thursday, June 13, 8:25 AM "We believe the timing of the deal reflects Amgen's confidence in the program," Needham's Chad Messer says of yesterday's strategic collaboration expansion between Cytokinetics (CYTK) and Amgen (AMGN). Like SA contributor Smith On Stocks, Messer likes the prospects for Omecamtiv in Phase IIb clincals and says that while "the primary endpoint is the reduction of dyspnea … we believe as long as AMGN concludes there is sufficient efficacy to support starting a pivotal trial, CYTK shares should stage a significant rally." Messer's CYTK PT is now $3.50, representing a 150% upside. Shares +2% premarket. Comment! [Healthcare]
Wednesday, June 12, 2:20 PM A bit of sell-side commentary regarding Amgen's (AMGN -1.6%) announcement of top-line data from a Phase 3 trebananib trial (previous): DB analyst Robyn Karnauskas notes that sales of the treatment are not factored into the bank's estimates and as such, any "success would present upside to estimates." Karnauskas also likes the "positive" data released on the Psoriatic arthritis treatment Brodalumab. Nevertheless, concerns about Enbrel's competitive edge over cheaper generics are weighing on shares. (Other Psoriatic arthritis news: Apremilast effective) Comment! [Healthcare, On the Move]
Wednesday, June 12, 10:47 AM Cytokinetics (CYTK +10%) trades higher coming off an earlier trading halt following the company's announcement that it's expanded its strategic collaboration with Amgen (AMGN -0.7%) to include Japan. In 2006, the two companies entered into a deal to develop and commercialize small-molecule therapeutics for the treatment of heart failure, with omecamtiv mecarbil as their most advanced candidate. Initially, CYTK's license to AMGN excluded Japan, but under the expansion, it will now include Japan and cover additional products as well. Comment! [Healthcare, On the Move]
Wednesday, June 12, 9:20 AM A Phase 3 trial of the angiopoietin inhibitor trebananib plus paclitaxel in ovarian cancer patients meets its primary endpoint of progression-free survival, Amgen (AMGN) says. The Hazard ratio was 0.66, indicative of a "34% reduction in the risk of disease progression or death." Shares +0.98% premarket. (PR) Comment! [Healthcare]
Wednesday, June 12, 3:08 AM Amgen's (AMGN) blockbuster Enbrel drug for treating rheumatoid arthritis, which generated sales of $4.23B last year, is no more effective than a combination of three generic treatments, a study shows. While a regimen that includes Enbrel costs $25,000 a year per patient, the "triple therapy" costs just $1,000. The research didn't examine similar drugs from AbbVie (ABBV) or Johnson & Johnson (JNJ), although many doctors consider them to be equivalent to Enbrel. Despite the study, researchers feel that the branded treatments might be too well ensconced to be quickly replaced. 4 Comments [Healthcare, Top Stories]
Monday, June 3, 11:43 AM Amgen (AMGN -3.1%) slips today as analysts give a muted response to its experimental skin-cancer drug, T-Vec, despite delivering better-than-expected study data at ASCO. The problem is a new class of PD-1 immunotherapy drugs from Merck (MRK) and Bristol-Myers (BMY) are dominating the field. RBC predicts they'll "eventually usher in new standard of care" for melanoma, and limiting T-Vec's sales potential to only around $300M to $500M annually - which isn't much considering the multibillion-dollar market potential for PD-1 drugs. Comment! [Healthcare, On the Move]
Wednesday, May 29, 8:05 AM Amgen (AMGN -0.6%) forms a JV with Japan's Astellas Pharma (ALPMF.PK) to develop and sell five new drugs in the latter's home country, with the hope being to launch the first medicine in 2016. The JV should help Amgen partly fill what it has described as "a noticeable gap" - its absence from China and Japan. (PR) Comment! [Healthcare]
Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 7:33 AM Transgenomic (TBIO.OB) enters into a collaborative agreement with Amgen (AMGN) for the further development of a CE-IVD test for the detection of RAS mutations in patients with metastatic colorectal cancer. (PR) Comment! [Healthcare]
Friday, May 3, 5:43 PM An FDA panel has voted 17-1 that Amgen's (AMGN) blood-boosting drugs would benefit radiation survivors in the event of a nuclear attack. The drugs, known as Leukocyte growth factor drugs, are normally given to cancer patients to combat the effects of chemotherapy. The panel observed monkeys exposed to radiation, and those given AMGN's Neupogen showed a greater likelihood of survival, and the FDA says it's likely to provide the same benefit to people as well. Comment! [Healthcare]
Friday, May 3, 4:18 PM By a 17-1 margin, the FDA votes Amgen's (AMGN +0.8%) Neulasta and Neupogen drugs could improve survival rates for people exposed to radiation following a nuclear attack. Bloomberg recently observed Neulasta and Neupogen , which are used to prevent infection during chemotherapy, collectively produced ~$5.4B in 2012 sales for Amgen. Comment! [Healthcare]

REHeakins
$AMGN buy @ 101 & sell Jan 14 110 call @ $3.55 + 3 div. for an 8.4% annual return if not called.
12 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Nice move today and a vote of confidence from $AMGN. $CYTK current move has a long way to go.
Wed, 9:48 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Philip Davis
Morning Outlook: Cashing Nikkei Longs, QE Reaching It's Limit? $$ $EWJ, $USO, $GLD, $BA $CAT $AMGN $VOD #Futures --http://bit.ly/13Bjtai
Wed, 6:02 AM
Reply (1)

• !Report Abuse
View all 1 replies
jason2713: Thanks Phil, always enjoy reading your emails you send me.
Wed, 7:06 AM
• !Report Abuse
Add a reply...

140 characters

Chines33
$AMGN I am regretting covering that short from 110 to 106. What mistake now under 95. Sigh.
Jun 5, 6:05 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
$AMGN breaking down. A short I should have stuck with longer.
May 20, 1:40 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$AMGN confirmed breakdown below 103.31 http://bit.ly/162rjzE
May 20, 12:43 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
Have You Checked Your Bios Lately? http://bit.ly/13bVP2D $QQQ $AMGN $SPY $DIA $SPX
May 12, 6:15 PM
Reply (1)

• !Report Abuse
View all 1 replies
realornot: Bio sign for market is something like 180/120 !!!!
May 12, 6:29 PM
• !Report Abuse
Add a reply...

140 characters

StockConsultant
$AMGN nice move off of support today, charts analysis http://goo.gl/emtGn
May 10, 3:13 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$AMGN holding double support, very good upside trade quality http://goo.gl/BHXAl
May 9, 12:47 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
Strong $AMGN back to double support http://goo.gl/6fHRr
May 2, 3:01 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Philip Davis
Morning Outlook: Cashing Nikkei Longs, QE Reaching It's Limit? $$ $EWJ, $USO, $GLD, $BA $CAT $AMGN $VOD #Futures --http://bit.ly/13Bjtai
Wed, 6:02 AM
Reply (1)

• !Report Abuse
View all 1 replies
jason2713: Thanks Phil, always enjoy reading your emails you send me.
Wed, 7:06 AM
• !Report Abuse
Add a reply...

140 characters

Jason F
Have You Checked Your Bios Lately? http://bit.ly/13bVP2D $QQQ $AMGN $SPY $DIA $SPX
May 12, 6:15 PM
Reply (1)

• !Report Abuse
View all 1 replies
realornot: Bio sign for market is something like 180/120 !!!!
May 12, 6:29 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
$YUM only positive tonight. $AAPL $VMW $AMGN $T $JNPR $PNRA $EW gothically awful
Apr 23, 6:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
paulalmony: $BRCM positive
Apr 24, 1:22 AM
• !Report Abuse
Add a reply...

140 characters

Chines33
Lost in all the $AAPL talk was the $AMGN quarter. This has been a stealth mover higher for biotech. Now raises questions.
Apr 23, 8:44 PM
Reply (2)

• !Report Abuse
View all 2 replies
Chines33: The entire biotech sector has been parabolic for the past month, and $AMGN first to report a disaster here. Curious to see reaction from:
Apr 23, 8:45 PM
• !Report Abuse
Chines33: $CELG $GILD $REGN etc etc
Apr 23, 8:45 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
3 trades today. One smaller winner in $AMGN short 103.07-103.22. A loss I $AAPL 433.50 out 430.75. An my biggest scalp of year $CJES 22.84
Apr 1, 8:14 PM
Reply (4)

• !Report Abuse
View all 4 replies
Chines33: Scalp meaning less then a few hours position.
Apr 1, 8:17 PM
• !Report Abuse
fatfat: hey, i sold out of money uncovered puts today. maybe i match it with uncovered calls if apple rallies tomorrow - a naked weeklie straddle..
Apr 1, 8:34 PM
• !Report Abuse
Add a reply...

140 characters

Workinprogress
Juggling and analyzing a variety of assets including: $FB, $LNG, $AMGN, $MTX, $IRV, and $PTSM.
Mar 20, 10:48 PM
Reply (2)

• !Report Abuse
View all 2 replies
Workinprogress: *$PSMT
Mar 20, 10:49 PM
• !Report Abuse
Workinprogress: Sorry, wrong ticker: $PETM
Mar 20, 10:52 PM
• !Report Abuse
Add a reply...

140 characters

Dr. Kris
When was the last time anyone mentioned Amgen (AMGN)? Don't look now, but it broke $72 resistance to its highest level since 2007...
6/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Dr. Kris: ...Interesting article on how Amgen is acting like like big pharma: http://seekingalpha.com/a/bbw7
6/18/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYTK: Wall St completely ignoring great results of ALS and HF drugs. AMGN should just buy them out. Ridiculously undervalued at $70M
5/24/12
Reply (2)

• !Report Abuse
View all 2 replies
The Scientist: Omecamtiv is a wonder drug that can be used in the ICU like water. It raises CO/SV; lowers BP/HR. Too good to be true.
5/24/12
• !Report Abuse
briandiplacido: As a long-time ICU nurse who's seen tons of tachyarrythmia from inotropes, I agree (seems too good to be true). Interesting.
5/24/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
Some more solid moves today. ZLTQ MX PKT DATE SKUL STX AMGN DRD AZPN CBOE GRMN EXC PZZA SBUX #ZLTQ #MX #PKT #DATE #SKUL #STX #AMGN #CBOE
11/7/11
Reply (3)

• !Report Abuse
View all 3 replies
Brandon Gibbs: i love that PZZA but i feel like i missed the boat..
11/7/11
• !Report Abuse
Ocean Man: STX was up a penny.
11/8/11
• !Report Abuse
Add a reply...

140 characters

AMGN Amgen Inc.

AMGN

Amgen Inc.